Similarly, pegylated arginine deiminase (ADI-PEG20), a modified enzyme which can be administered to degrade arginine and thus activate GCN2, has shown favorable results in clinical trials in AML patients in combination with low-dose cytarabine [91], although is ineffective against relapsed/refractory patients [92]. Here, EIF2AK4 is linked to acute myeloid leukemia.